Glimisave M1 850 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 850mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby enhancing insulin secretion and improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity without causing significant hypoglycemia. This combination offers complementary mechanisms of action, making it effective in patients inadequately controlled by diet and exercise alone or those requiring dual therapy. The prolonged-release formulation ensures a steady plasma concentration, reducing dosing frequency and improving patient compliance. Glimisave M1 850 Tablet PR should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular blood glucose monitoring. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and potential risk of hypoglycemia. Regular monitoring of renal function and blood glucose levels is recommended during therapy. This combination therapy provides an effective approach to glycemic control in type 2 diabetes patients requiring dual oral antidiabetic agents.